AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

IRVINE, Calif.: IRVINE, Calif., June 8, 2021 /PRNewswire/ -- AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, today announced data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma (GBM). The analysis focused on the...

Click to view original post